Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load

Journal of Immunology

Volumn 165, Issue 3, 2000, Pages 1692-1704

  Mollet, Lucile ^a   Li, Tai Sheng ^a   Samri, Assia ^a   Tournay, Claire ^b   Tubiana, Roland ^c   Calvez, Vincent ^d   Debré, Patrice ^a   Katlama, Christine ^c   Autran, Brigitte ^a,e  

^a Laboratoire d'Immunologie Cellulaire et Tissulaire CNRS URA 625   (France)

^b Immunotech   (France)

^c Dept des Maladies Infectieuses ^*  (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; VIRUS LOAD;

EID: 0034254206     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.3.1692     Document Type: Article

References (64)

1. + T cells. Science 280:227.
2. + lymphocytes. Science 283:857.
3. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991.
4. Gotch, F. M., D. F. Nixon, N. Alp, A. J. McMichael, and L. K. Borysiewicz. 1990. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol. 2:707.
5. Hoffenbach, A., P. Langlade-Demoyen, G. Dadaglio, H. Vilmer, F. Michel, C. Mayaud, B. Autran, and F. Plata. 1989. Unusually high frequencies of HIV-specitic cytotoxic T lymphocytes in human. J. Immunol. 142:452.
6. Moss, P. A., S. L. Rowland-Jones, P. M. Frodsham, S. McAdam, P. Giangrande, A. J. McMichael, and J. I. Bell. 1995. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. Natl. Acad. Sci. USA 92:5773.
7. Koup, R. A., C. A. Pikora, K. Luzuriaga, D. B. Brettler, H. S. Day, G. P. Mazzara, and J. L. Sullivan. 1991. Limiting dilution analysis of cytoloxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J. Exp. Med. 174:1593.
8. Klein, M. R., C. A. Van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keel, J. K. Eeftinck Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365.
9. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
10. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177.
11. Ogg, G. S., and A. J. McMichael. 1998. HLA-peptide tetrameric complexes. Curr. Opin. Immunol. 10:393.
12. + T cells during an acute virus infection. Immunity 8:167.
13. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.
14. Ogg, G. S., X. Jin, S. Bonhoeffer, P. Moss, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, A. Hurley, et al. 1999. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73:797.
15. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162:1780.
16. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 96:5692.
17. Kalams, S. A., P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg, and B. D. Walker. 1999. Levels of human immunodeficiency virus type 1-specific cytoloxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721.
18. + responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 73:7108.
19. Haas, G., U. Plikal, P. Debré, M. Lucchiari, C. Katlama, Y. Dudoit, O. Bonduelle, M. Bauer, H. G. Ihlenfeldt, G. Jung, et al. 1996. Dynamics of viral variants in HIV-1 Nef and specific cytoloxic T lymphocytes in vivo. J. Immunol. 157:4212.
20. Wilson, C. C., S. A. Kalams, B. M. Wilkes, D. J. Ruhl, F. Gao, B. H. Hahn, I. C. Hanson, K. Luzuriaga, S. Wolinsky, R. Koup, et al. 1997. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J. Virol. 71:1256.
21. Wolinsky, S. M., B. T. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, and J. T. Safrit. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537.
22. + T cell homeostasis and function in advanced HIV disease. Science 277:112.
23. Pakker, N. G., D. W. Notermans, R. J. De Boer, M. T. Roos, F. De Wolf, A. Hill, J. M. Leonard, S. A. Danner, F. Miedema, and P. T. Schellekens. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4:208.
24. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
25. Cheynier, R., S. Henrichwark, F. Hadida, B. Pelletier, E. Oksenhendler, B. Autran, and S. Wain-Hobson. 1994. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78:373.
26. Plata, F., B. Autran, L. P. Martins, W.-H. S., M. Raphael, C. Mayaud, M. Denis, J. M. Guillon, and P. Debré. 1987. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 328:348.
27. Tenner-Racz, K., H. J. Stellbrink, J. van Lunzen, C. Schneider, J. P. Jacobs, B. Raschdorff, G. Grosschupff, R. M. Steinman, and P. Racz. 1998. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation: the impact of highly active antiretroviral therapy. J. Exp. Med. 187:949.
28. Dalod, M., M. Harzic, I. Pellegrin, B. Dumon, B. Hoen, D. Sereni, J. C. Deschemin, J. P. Levy, A. Venet, and E. Gomard. 1998. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 178:61.
29. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination. Nat. Med. 5:512.
30. Neumann, A. U., R. Tubiana, V. Calvez, C. Robert, T. S. Li, H. Agut, B. Autran, and C. Katlama. 1999. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment: Comet Study Group. AIDS 13:677.
31. Ortiz, G. M., D. F. Nixon, A, Trkola, J. Binley, X. Jin, S. Bonhoeffer, P. J. Kuebler, S. M. Donahoe, M. A. Demoitie, W. M. Kakimoto, et al. 1999. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104:R13.
32. Li, T. S., R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351:1682.
33. Parker, K. C., M. A. Bednarek, L. K. Hull, U. Utz, B. Cunningham, H. J. Zweerink, W. B. Biddison, and J. E. Coligan. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2. J. Immunol. 149:3580.
34. Van der Burg, S. H., M. R. Klein, C. J. Van de Velde, W. M. Kast, F. Miedema, and C. J. Melief. 1995. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 9:121.
35. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276.
36. Scotet, E., J. David-Ameline, M. A. Peyrat, A. Moreau-Aubry, D. Pinczon, A, Lim, J. Even, G. Semana, J. M. Berthelot, R. Breathnach, M. Bonneville, and E. Houssaint. 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184:1791.
37. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1605.
38. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, M. Roederer, and M. M. Davis. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677.
39. + T cells in primary and secondary influenza pneumonia. Immunity 8:683.
40. + T cells. Proc. Natl. Acad. Sci. USA 96:8597.
41. Goulder, P. J., A. K. Sewell, D. G. Lalloo, D. A. Price, J. A. Whelan, J. Evans, G. P. Taylor, G. Luzzi, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1997. Patterns of immunodominance in HIV-1-specitic cytoloxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185:1423.
42. Brander, C., and B. Walker. 1996. The HLA-class 1 restricted CTL response in HIV-1 infection: identification of optimal epitopes. In HIV-1 Molecular Immunology Database, vol. 3. B. Korber, B. Walker, R. Koup, B. Haynes, J. Moore, and C. Brander, eds. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, Part III.
43. Nixon, D. F., A. R. Townsend, J. G. Elvin, C. R. Rizza, J. Gallwey, and A. J. McMichael. 1988. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides Nature 336:484.
44. Zhang, Q. J., R. Gavioli, G. Klein, and M. G. Masucci. 1993. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc. Natl. Acad. Sci. USA 90:2217.
45. Threlkeld, S. C., P. A. Wentworth, S. A. Kalams, B. M. Wilkes, D. J. Ruhl, E. Keogh, J. Sidney, S. Southwood, B. D. Walker, and A. Sette. 1997. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J. Immunol. 159: 1648.
46. Sipsas, N. V., S. A. Kalams, A. Trocha, S. He, W. A. Blattner, B. D. Walker, and R. P. Johnson. 1997. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J. Clin. Invest. 99:752.
47. Johnson, R. P., A. Trocha, T. M. Buchanan, and B. D. Walker. 1992. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type I envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. Exp. Med. 175:961.
48. Koenig, S., T. R. Fuerst, L. V. Wood, R. M. Woods, J. A. Suzich, G. M. Jones, V. A. De la Cruz, R. T. J. Davey, S. Venkatesan, B. Moss, W. E. Biddison, and A. S. Fauci. 1990. Mapping the fine specificity of a cytolytic T cell response to HIV-1 Nef protein. J. Immunol. 145:127.
49. + T cells in the central region of the HIV-1 NEF protein. J. Immunol. 146:1560.
50. Hadida, F., A. Parrot, M. P. Kieny, B. Sadat-Sowti, C. Mayaud, P. Debré, and B. Autran. 1992. Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs: an in vitro limiting dilution analysis. J. Clin. Invest. 89:53.
51. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569.
52. Solache, A., C. L. Morgan, A. I. Dodi, C. Morte, I. Scott, C. Baboonian, B. Zal, J. Goldman, J. E. Grundy, and J. A. Madrigal. 1999. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J. Immunol. 163:5512.
53. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180:1283.
54. + T cells. J. Exp. Med. 186:1407.
55. Gallimore, A., A. Glithero, A. Godkin, A. C. Tissot, A. Pluckthun, T. Elliott, H. Hengartner, and R. Zinkernagel. 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187:1383.
56. Lederman, M. M., E. Connick, A. Landay, D. R. Kuritzkes, J. Spritzler, M. St. Clair, B. L. Kotzin, L. Fox, M. H. Chiozzi, J. M. Leonard, et al. 1998. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J. Infect. Dis 178:70.
57. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J. Clin. Invest. 103:1391.
58. Nakajima, H., H. Sano, T. Nishimura, S. Yoshida, and I. Iwamoto. 1994. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J. Exp. Med. 179:1145.
59. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947.
60. + T cells closely correlates with CD56 surface expression. J. Immunol. 164:1148.
61. Wong, J. K., H. F. Gunthard, D. V. Havlir, Z. Q. Zhang, A. T. Haase, C. C. Ignacio, S. Kwok, E. Emini, and D. D. Richman. 1997. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc. Natl. Acad. Sci. USA 94:12574.
62. Cavert, W., D. W. Notermans, K. Staskus, S. W. Wietgrefe, M. Zupancic, K. Gebhard, K. Henry, Z. Q. Zhang, R. Mills, H. McDade, et al. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1. Science 276: 960.
63. Lisziewicz, J., E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori. 1999. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med 340:1683.
64. + T-cell reactivity to cytomegalovirus after HAART in an HIV-1-infected patient. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:514.